VEEV Veeva Systems
$307.39
▼ 1.8%Updated Oct 16, 2:25 PM ET
Report Card
VEEV at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Favorable · 64/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▼ Down 45.5% in the year to Jul 6, 2026
Key Metrics
Market Cap
$30.68B
P/E
52.02x
Forward P/E (est.)
43.38x
ROE
13.4%
Revenue Growth
16.3%
EPS Growth
19.9%
Profit Margin
28.4%
FCF Yield
2.1%
Debt / Equity
0x
ROIC
10.0%
Interest Coverage
—
Current Ratio
4.74x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
64/100
Business Overview
Veeva Systems (VEEV) is a large-cap company in the Health Care Technology industry, part of the Health Care sector of the S&P 500, with a market value around $30.68B.
In its latest reported year it generated about $3.20B in revenue and $908.91M in net profit.
Our model rates VEEV Favorable (64/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (10 years of history).
Profit margins and economic moats, explainedThe filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
73.8% average over the last 3 years
±2.0 pts around 72.0% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 10 of 10 years
10.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what VEEV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. VEEV trades near $307.39, above its 50-day average ($165.49) and 200-day average ($213.36). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 75 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. VEEV's is $7.35 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, VEEV found buyers near $150.39 (support) and sellers near $192.90 (resistance); its 52-week range then was $148.05–$310.50. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
4Y CAGR
14.6%
Revenue moved from $550.54M in 2017 to $3.20B in 2026, a 21.6% compound annual growth rate. The most recent year grew a strong 16.3% year over year. Consistent top-line growth is one sign of healthy demand.
Profitability
Gross Margin
75.5%
Operating Margin
28.7%
Net Margin
28.4%
ROE
13.4%
Veeva Systems keeps about 28.4% of each sales dollar as net profit, with a 75.5% gross margin and 28.7% operating margin. Return on equity is 13.4% and return on invested capital about 10.0%. Margins this wide usually signal pricing power or a cost advantage.
Debt Analysis
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 4.7x. That is a conservative balance sheet — a cushion in downturns.
Cash Flow Analysis
Operating CF
$1.42B
Free Cash Flow
$1.42B
FCF Margin
44.3%
In the latest year Veeva Systems produced about $1.42B of operating cash flow and $1.42B of free cash flow after capital spending. That is a free-cash-flow yield of about 2.1% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
52.02x
P/S
8.15x
P/B
8.72x
EV / EBITDA
—
VEEV trades at 52.0x trailing earnings (about 43.4x on estimated forward earnings), 8.1x sales, and 8.7x book value. That is a rich multiple that prices in a lot of future growth.
Metrics vs. Sector Range
Where VEEV sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How VEEV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, VEEV ranks #20 by our overall rating. It trades at a premium versus the sector on earnings (52x P/E vs. 26.1x median) with a lower return on equity (13.4% vs. 14.1%) and faster revenue growth (16.3% vs. 7.6%).
P/E vs sector
52x
median 26.1x
ROE vs sector
13.4%
median 14.1%
Growth vs sector
16.3%
median 7.6%
Sector rank
#20
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$583.74 – $979.18
vs. $307.39 today · implied CAGR 14% – 26%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $4.30B | $4.99B | $5.79B | $6.71B |
| Net income | $1.04B | $1.20B | $1.40B | $1.62B | $1.88B |
| EPS | $10.40 | $12.06 | $13.99 | $16.23 | $18.83 |
| Share price (low) | $322.40 | $373.98 | $433.82 | $503.23 | $583.74 |
| Share price (high) | $540.79 | $627.32 | $727.69 | $844.12 | $979.18 |
| CAGR (low–high) | 5% / 76% | 10% / 43% | 12% / 33% | 13% / 29% | 14% / 26% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.
Bull Case
The case for VEEV:
- Revenue is growing 16.3% a year, a sign of real demand.
- High net margins (28.4%) point to pricing power or efficiency.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Favorable (64/100).
Bear Case
The case against VEEV:
- A rich 52.0x earnings multiple prices in a lot of growth.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Valuation risk — at 52.0x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen favourably: Veeva Systems is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 52.0x earnings, which our model scores Favorable (64/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Latest SEC Filings
VEEV's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
In the Idea Lab
VEEV — frequently asked questions
Is VEEV a good stock to buy?
We don't give buy or sell advice. Our model rates Veeva Systems Favorable (64/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is VEEV's rating on The Stocks School?
Veeva Systems currently scores 64/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does VEEV's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Veeva Systems's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for VEEV calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this VEEV analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell VEEV. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.